For example, using a combination treatment of JQ1, an inhibitor for BRD4, and NSC, an inhibitor of RAC1, leads to a decrease in Myc expression and, in turn, reduces G9a-Myc complex formation in HER-2 and triple-negative breast cancer [188]. Here, MYC is linked to triple-negative breast carcinoma.